Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter, 3-Period, 14-Day Crossover Study to Determine the 24-h Lung Function Profile of Indacaterol (300 microg once daily) in Patients With Moderate-to-Severe COPD, Using Open-Label Salmeterol (50 microg twice per day) as Active Control

X
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter, 3-Period, 14-Day Crossover Study to Determine the 24-h Lung Function Profile of Indacaterol (300 microg once daily) in Patients With Moderate-to-Severe COPD, Using Open-Label Salmeterol (50 microg twice per day) as Active Control

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Indacaterol (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 Nov 2009 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
    • 04 Nov 2009 Results reported at the 75th Annual Meeting of the American College of Chest Physicians: Chest 2009.
    • 10 Jul 2009 Actual patient number (68) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top